Companies to collaborate on an exclusive basis on Alizé Pharma's unacylated ghrelin (AZP-01) program for the treatment of type II diabetes.
26 January, 2010
Rexahn Pharmaceuticals announces that the European Patent Office has granted a patent for its novel anti-cancer compound, RX-3117.
21 January, 2010
Astex Therapeutics announced recently that AstraZeneca has selected a clinical candidate from the PKB inhibitor collaborative programme.
08 January, 2010